HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bilateral hearing loss during vincristine therapy: a case report.

Abstract
Vincristine sulfate is a chemotherapeutic agent used in different cancer therapies. It is also the first choice of treatment for peripheral T-cell lymphoma with cyclophosphamide and adriamycin. Sudden hearing loss during vincristine therapy is a very rare event. This is a case of a 16-year old girl who developed sudden bilateral hearing loss related to vincristine therapy.
AuthorsM T Kalcioglu, I Kuku, E Kaya, S Oncel, I Aydogdu
JournalJournal of chemotherapy (Florence, Italy) (J Chemother) Vol. 15 Issue 3 Pg. 290-2 (Jun 2003) ISSN: 1120-009X [Print] England
PMID12868558 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Vincristine
Topics
  • Adolescent
  • Antineoplastic Agents, Phytogenic (administration & dosage, adverse effects)
  • Audiometry
  • Disease Progression
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Fatal Outcome
  • Female
  • Hearing Loss, Sensorineural (chemically induced, diagnosis)
  • Humans
  • Lymphoma, T-Cell (diagnosis, drug therapy)
  • Risk Assessment
  • Vincristine (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: